Celltrion Files Phase 3 Trial Plan for CT-P13 SC in Rheumatoid Arthritis, Expanding Indications Beyond Inflammatory Bowel Disease
Celltrion has submitted a Phase 3 clinical trial plan to the Korean Ministry of Food and Drug Safety for CT-P13 SC subcutaneous injection to expand its indication to rheumatoid arthritis.
This trial aims to broaden the therapeutic scope of CT-P13 SC, which is already approved for inflammatory bowel diseases, to rheumatoid arthritis patients.
The study enrolls 296 patients over 52 weeks, with the primary endpoint of demonstrating superiority over placebo in ACR50 response rate at week 12.
Investors should note that the statistical probability of a clinical trial drug receiving final marketing approval is approximately 10%, as disclosed.
[AI Summary]Celltrion's CT-P13 SC is already commercialized for ulcerative colitis and Crohn's disease; this RA trial is an attempt to secure additional growth through indication expansion. However, given the inherent uncertainty and low approval probability, near-term stock price impact is likely limited, and long-term value creation hinges on trial outcomes.
KOSPI Filing Information
Material Information Regarding Investment Decision (Application for Korean Phase 3 Clinical Trial Plan for CTP13 SC (Zimpentra) for Rheumatoid Arthritis Patients)